

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Kaisa Health Group Holdings Limited**

**佳兆業健康集團控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 876)**

### **PROFIT WARNING**

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 (the “**Period**”) and information currently available to the Board, the Group expects to record a net loss in a range between HK\$22 million and HK\$26 million for the Period as compared to the net profit of approximately HK\$39 million for the six months ended 30 June 2023. Such change from net profit to net loss for the Period is mainly due to a one-off gain on disposal of subsidiaries of approximately HK\$68 million recorded for the six months ended 30 June 2023.

The Company is still in the process of finalising the interim results of the Group for the Period. The information contained in this announcement is only based on the unaudited consolidated management accounts of the Group and information currently available to the Group, which is subject to finalisation and necessary adjustments and has neither been confirmed or reviewed by the auditors of the Company or the audit committee of the Company. Details of the unaudited financial results of the Group for the Period will be disclosed in the Group’s interim results announcement for the Period, which will be published in due course pursuant to the requirements of the Listing Rules. Shareholders and potential investors are advised to read the interim results announcement carefully when it is published.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Kaisa Health Group Holdings Limited**  
**Kwok Ying Shing**  
*Chairman*

Hong Kong, 21 August 2024

*As at the date of this announcement, the Board comprises Mr. Kwok Ying Shing (Chairman) and Mr. Luo Jun as executive Directors; and Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying as independent non-executive Directors.*